Results 291 to 300 of about 2,997,712 (340)

Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Renin–angiotensin–aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi therapy, guidelines suggest managing hyperkalaemia using newer potassium binders such as sodium zirconium ...
Charles V. Pollack Jr.   +9 more
wiley   +1 more source

Qualitative analysis of cardiovascular disease prevention in dental practice. [PDF]

open access: yesPublic Health Pract (Oxf)
O'Farrell Á   +3 more
europepmc   +1 more source

Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry)

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF with reduced ejection fraction (HFrEF) a pharmacological approach based on four fundamental drugs to be rapidly implemented and then uptitrated to modify disease progression.
Stefania Paolillo   +62 more
wiley   +1 more source

Experiences of Lesbian, Gay, Bisexual, Transgender, and Queer Cardiology Physicians and Fellows in Training. [PDF]

open access: yesJACC Adv
Cook SC   +8 more
europepmc   +1 more source

Effect of Renal Impairment on Clinical Outcomes After Mitral Valve Transcatheter Edge-to-Edge Repair. [PDF]

open access: yesJACC Asia
Tanaka K   +30 more
europepmc   +1 more source

Delivering guideline-directed medical therapy for heart failure with reduced ejection fraction as an over-encapsulated polypill: rationale and protocol for the COMBO-HF-X pilot crossover randomised clinical trial. [PDF]

open access: yesBMJ Open
DeJong C   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy